IMNM Past Earnings Q&A
What was the best and worst IMNM past earnings results?
For Immunome, I'm wondering what the company's very best and worst earnings results have been, on an earnings per share basis?
The highest IMNM past earnings result in our data set was -0.370/share posted in Q1 2021, while the lowest was in Q3 2020 when IMNM posted -7.520/share.
The biggest top line earnings performance — aka revenue — quarter was in Q3 2022 when IMNM reported NA in revenue, while the quarter with the lowest revenue in our data set was Q3 2022 at NA of revenue.
There are 9 IMNM past earnings results in our data set.
On this page we presented the IMNM past earnings date information for Immunome. Reviewing that
IMNM Past Earnings
for the company, we see that the highest past earnings result in our data set was in Q1 2021, when IMNM posted gaap of -0.370/share. Meanwhile the lowest IMNM past earnings result was in Q3 2020, when IMNM posted gaap of -7.520/share. Turning to top line revenue performance, the biggest revenue quarter in our data set was seen in Q3 2022 when IMNM reported NA in revenue, while the smallest revenue quarter was Q3 2022 when IMNM reported NA in revenue.
Any self directed investor doing their due diligence on IMNM or any other given stock can benefit from
researching all of the Immunome past earnings — and here, we present each quarter's result all together
on one page for easy comparison. Studying this information can help when projecting future earnings, as well
as determining whether the past earnings trajectory justifies the current stock value.
That's why we bring you PastEarnings
.com to make it easy for investors to investigate
Immunome past earnings, or the past earnings information for any stock in our coverage universe.
And in your continued research we hope you will be sure to check out the further links included for earnings
surprises history (beat/miss data) as well as next earnings dates for IMNM. Thanks for visiting, and the next
time you need to research IMNM past earnings
or those of another stock, we hope you'll think of our site, as your
go-to past earnings research resource of choice.